Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7753044 | 0.90 | POLB (0.39) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL6687766 | 0.87 | ALDH1A1 (0.42) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL2002799 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL10980060 | 0.83 | KMT2A (0.38) | ALDH1A1SMN1; SMN2HPGDPKMKMT2A | |
| SCHEMBL5162362 | 0.82 | HPGD (0.38) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL8082242 | 0.76 | EHMT2 (0.38) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL9398036 | 0.75 | ITGB3 (0.40) | ALDH1A1KMT2AATMMEN1POLB | |
| SCHEMBL177980 | 0.75 | ALDH1A1 (0.48) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL616908 | 0.75 | ALDH1A1 (0.54) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM | |
| SCHEMBL7421417 | 0.73 | SMN1; SMN2 (0.55) | ALDH1A1HSD17B10SMN1; SMN2HPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281628-A1 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-11 | — | — | US | claimed |
| EP-4392087-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028082-A2 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2009077438-A1 | METHOD FOR PREPARING PROTEIN CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2009-06-25 | — | — | WO | claimed |
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | claimed |
| EP-1740954-A1 | MASS SPECTROMETRY OF ANTIBODY CONJUGATES | Kadkhodayan, Miryam (US) | 2007-01-10 | — | — | EP | claimed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | claimed |
| WO-2005101017-A1 | MASS SPECTROMETRY OF ANTIBODY CONJUGATES | GENENTECH, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | claimed |
| WO-2005086775-A2 | LUMEN-EXPOSED MOLECULES AND METHODS FOR TARGETED DELIVERY | UTAH VENTURES II, L.P. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20040146516-A1 | Lumen-exposed molecules and methods for targeted delivery | UTAH VENTURES II L.P. | 2004-07-29 | — | — | US | claimed |
| EP-1206251-A4 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2004-06-30 | — | — | EP | claimed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | claimed |
| EP-1206251-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 2002-05-22 | — | — | EP | claimed |
| WO-2000066090-A1 | AMPLIFICATION OF FOLATE-MEDIATED TARGETING TO TUMOR CELLS USING NANOPARTICLES | BIOTECH AUSTRALIA PTY LIMITED (AU) | 2000-11-09 | — | — | WO | claimed |
| EP-0308936-B1 | Antibody heteroconjugates for the killing of HIV-infected cells | BRISTOL MYERS SQUIBB CO (US) | 1994-07-06 | — | — | EP | claimed |
| JP-2173000-A | — | — | None | — | — | JP | disclosed |
| JP-8053499-A | — | — | None | — | — | JP | disclosed |
| EP-0040365-B1 | AN ASSAYING METHOD INVOLVING BIOSPECIFIC AFFINITY REACTIONS | PHARMACIA DIAGNOSTICS AB (SE) | 1985-08-21 | — | — | EP | disclosed |
| US-4507234-A | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060127310-A1 | Amplification of biotin-mediated targeting | BTD, HLCS, SLC1A5 | ALDH1A1 1010/4885HSD17B10 4046/4885SMN1; SMN2 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.